Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AEON Biopharma (AEON)
NYSE MKT:AEON
AEON Biopharma (AEON) Stock Price & Analysis
19 Followers
AEON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.38 - $17.17
Previous Close$1.53
Volume68.49K
Average Volume (3M)97.14K
Market Cap
$59.86M
Enterprise Value$43.71M
Total Cash (Recent Filing)$16.20M
Total Debt (Recent Filing)$52.00K
Price to Earnings (P/E)-0.4
Beta0.54
Next Earnings
Mar 29, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding39,122,238
10 Day Avg. Volume103,389
30 Day Avg. Volume97,137
Standard Deviation0.18
R-Squared0.05
Alpha-0.00987
Financial Highlights & Ratios
Price to Book (P/B)-0.31
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda1.06
Forecast
1Y Price Target
$6.00Price Target Upside292.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
AEON Biopharma News
PremiumCompany Announcements
AEON Biopharma Halts Migraine Study and Evaluates Strategy
PremiumCompany Announcements
AEON Biopharma Phase 2 Migraine Treatment Trial Results
PremiumCompany Announcements
AEON Biopharma Bolsters Finance and Board with Daewoong Deal
PremiumCompany Announcements
AEON Biopharma Announces Warrant Exercise Deadline and TermsBulls Say, Bears Say
Bulls Say
Clinical Development EfficiencyEfficient and cost-effective clinical development is in sight for Aeon with the alignment on running two pivotal Phase 3 migraine trials under a single protocol.
Financial StabilityAeon's clinical development and ongoing projects are backed by strong financial stability, thanks to the completion of a $15M private placement.
Regulatory ConfidenceThe FDA's approval of Aeon's pivotal Phase 3 plan for ABP-450 reflects a strong vote of confidence in the drug's potential efficacy.
Bears Say
Clinical Trial ResultsABP-450's migraine program did not meet the primary endpoint.
Financial HealthThe company's balance sheet, with cash until June 2024, does not afford them the flexibility for the treatment's further development without additional funding.
Funding RequirementsAdditional funding needed to advance programs.
---
Ownership Overview
40.70% Insiders
0.92% Mutual Funds
21.60% Other Institutional Investors
36.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $1.38 and its highest was $17.17 in the past 12 months.
What is AEON Biopharma’s market cap?
Currently, no data Available
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is Mar 29, 2024 which is 51 days ago.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Nov 13, 2023. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $1.72.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Undervalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate is -$0.4.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 39,122,240 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of $1.19 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went down -1.196%.
Which hedge fund is a major shareholder of AEON Biopharma?
Among the largest hedge funds holding AEON Biopharma’s share is Saba Capital Management. It holds AEON Biopharma’s shares valued at N/A.
---
AEON Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (292.16% Upside)
$6.00 (292.16% Upside)
Hedge Fund Trend
Decreased
By 636.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-85.97%
Trailing 12-Months
Company Description
AEON Biopharma
Priveterra Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
---
AEON Stock 12 Month Forecast
Average Price Target
$6.00
▲(292.16% Upside)
Technical Analysis
Best Analysts Covering AEON
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-55.02%
reiterated a buy rating 4 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.02% per trade.
---